Eli Lilly and Co. withdrew its request for FDA approval to market its antidepressant Cymbalta for the treatment of chronic pain in the knee and back. The company said it intends to resubmit the application in the first half of next year, after it addresses the agency's concerns about Cymbalta's dosing and efficacy.

Related Summaries